CheckmAb Srl is an innovative start-up biotech company focused on the development of novel monoclonal antibodies for cancer immunotherapy, with the aim to provide safer and more effective therapies for patients. At present, the company is focused on the development of monoclonal antibodies for cancer immunotherapy, specifically targeting tumor-infiltrating regulatory T lymphocytes. These antibodies are expected to unleash the immunological response only within the neoplastic lesion, thereby avoiding harmful systemic autoimmune reactions that are too often associated with current immuntoherapies.